ArticleCancer immunology research2025

NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control.

Sara Majocchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.